The prices of leading cancer drugs have risen at rates far outstripping inflation over the last two decades, according to a new study co-authored by an Massachusetts Institute of Technology economist. But the exact reasons for the cost increases are unclear. Since 1995, a group of 58 leading cancer drugs has increased in price by 10% annually, even when adjusted for inflation and incremental health benefits, the study finds.
A research team from The Scripps Research Institute (TSRI), Mayo Clinic and other institutions has identified a new class of drugs that in animal models dramatically slows the aging process—alleviating symptoms of frailty, improving cardiac function and extending a healthy lifespan.
Prescription drugs spending jumped 13 percent last year, the biggest annual increase since 2003, according to the nation's largest pharmacy benefits manager.
Scientists have determined the basic structural organization of a molecular motor that hauls cargoes and performs other critical functions within cells. Biologists have long wanted to know how this molecular motor works. But the complex’s large size, myriad subunits and high flexibility have until now restricted structural studies to small pieces of the whole.
A new study has identified both where and how a protein in the brain, called Neuropeptide Y (NPY), can act to suppress binge alcohol drinking. The find suggests that restoring NPY may be useful for treating alcohol use disorders and may also protect some individuals from becoming alcohol dependent.
Bioengineers are presenting a network of pulsating cardiac muscle cells housed in an inch-long silicone device that effectively models human heart tissue. They have demonstrated the viability of this system as a drug-screening tool by testing it with cardiovascular medications.
A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans. The drug, called PAC-1, first showed promise in the treatment of pet dogs with spontaneously occurring cancers, and is still in clinical trials in dogs with osteosarcoma.
With antibiotic resistance on the rise, scientists are looking for innovative ways to combat bacterial infections. The pathogen that causes conditions from strep throat to flesh-eating disease is among them, but scientists have now found a tool that could help them fight it: a drug approved to treat HIV. Their work, appearing in ACS Chemical Biology, could someday lead to new treatments.
Scientists around the world make use of cell culture techniques on a daily basis. Whether they happen to be working with primary cell cultures, secondary cultures or cell lines, they all face many of the same problems: slow growth, spontaneous differentiation, evaporation, contamination and a host of other issues that require troubleshooting.
Researchers at the Univ. of North Carolina School of Medicine have found that the blood platelet protein Rasa3 is critical to the success of the common anti-platelet drug Plavix, which breaks up blood clots during heart attacks and other arterial diseases. The discovery details how Rasa3 is part of a cellular pathway crucial for platelet activity during clot formation.
An experimental antiviral drug shows some early, encouraging signs of effectiveness in its first human test against Ebola in West Africa, but only if patients get it when their symptoms first appear. A study of the drug, favipiravir, is still in early stages in West Africa, and too few people have been treated to really know whether the drug helps.
Case Western Reserve Univ. dental researcher Pushpa Pandiyan has discovered a new way to model how infection-fighting T cells cause inflammation in mice. The hope is that the discovery can lead to new therapies or drugs that jump-start weakened or poorly functioning immune systems. Pandiyan believes the process could lead to identifying and testing new drugs to replace antifungal medicines.
Chemical engineers have designed a new type of self-healing hydrogel that could be injected through a syringe. Such gels, which can carry one or two drugs at a time, could be useful for treating cancer, macular degeneration, or heart disease, among other diseases, the researchers say.
Researchers have long sought alternatives to morphine that curb its side effects, including dependency, nausea and dizziness. Now, an experiment at SLAC National Accelerator Laboratory has supplied the most complete atomic-scale map of such a compound docked with a cellular receptor that regulates the body’s pain response and tolerance.
Viruses are masters of outsourcing, entrusting their fundamental function– reproduction– to the host cells they infect. But it turns out this highly economical approach also creates vulnerability. Researchers have found an unexpected way the immune system exploits the flu virus’ dependence on its host’s machinery to create new viruses capable of spreading infection.
For patients with diabetes, insulin is critical to maintaining good health and normal blood-sugar levels. However, it’s not an ideal solution because it can be difficult for patients to determine exactly how much insulin they need to prevent their blood sugar from swinging too high or too low. Massachusetts Institute of Technology engineers hope to improve treatment for diabetes patients with a new type of engineered insulin.
It took 16 years of twists and turns. Over and over, Dr. Nancy Sullivan thought she was close to an Ebola vaccine, only to see the next experiment fail. "A case of resuscitation more than once," is how the National Institutes of Health researcher describes the journey.
For years, treating scratches and burns to the eyes has usually involved dropping medicine onto the eyes several times a day, sometimes for weeks: a treatment that lends itself to missed doses and other side effects. But scientists are now reporting a novel, drug-releasing wafer that patients can put directly on their affected eyes just once a day. The team says the device works better than drops and could help patients recover faster.
Federal health regulators on Tuesday approved a highly anticipated medicine from Pfizer Inc. to treat postmenopausal women with a certain type of advanced breast cancer who have not already taken other drugs. The Food and Drug Administration approved Ibrance for women who have tumors that do not contain a protein known as HER-2. Ibrance, known generically as palbociclib, works by blocking molecules linked to cancer cell growth.
Ten years after the 2005 Paris Declaration on Aid Effectiveness reported on the need for better coordination in the global fight against disease, global pharmaceutical supply chains remain fragmented and lack coordination, facing at least 10 fundamental challenges, according to a newly published paper.
President Barack Obama is calling for an investment to move away from one-size-fits-all-medicine, toward an approach that tailors treatment to your genes. The White House said Friday that Obama will ask Congress for $215 million for what he's calling a precision medicine initiative. The ambitious goal: Scientists will assemble databases of about a million volunteers to study their genetics to learn how to individualize care.
Low doses of metformin, a widely used diabetes medication and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, a Purdue Univ. study finds. Prostate cancer causes the second-highest number of cancer-related deaths in men in the U.S., and methods of treating advanced prostate cancer are limited.
A new study by Univ. of Kentucky Markey Cancer Center researchers suggests that targeting a key enzyme and its associated metabolic programming may lead to novel drug development to treat lung cancer. Cancer cells undergo metabolic alterations to meet the increased energy demands that support their excess growth and survival.
Lori Simons took the bright orange pill at 3 a.m. Eight hours later, doctors sliced into her brain, looking for signs that the drug was working. She is taking part in one of the most unusual cancer experiments in the nation. With special permission from the Food and Drug Administration and multiple drug companies, an Arizona hospital is testing medicines very early in development and never tried on brain tumors before.
Two new drug compounds appear to be effective in treating endometriosis, a disorder that, like MS, is driven by estrogen and inflammation, scientists report in Science Translational Medicine. The researchers hope to eventually use the new compounds and others like them to treat a variety of disorders linked to estrogen signaling and inflammation.